KZIA
Price:
$0.3715
Market Cap:
$17.82M
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.[Read more]
Industry
Biotechnology
IPO Date
1999-01-06
Stock Exchange
NASDAQ
Ticker
KZIA
According to Kazia Therapeutics Limited’s latest financial reports and current stock price. The company's current Current Ratio is 0.71. This represents a change of -11.42% compared to the average of 0.80 of the last 4 quarters.
The mean historical Current Ratio of Kazia Therapeutics Limited over the last ten years is 6.84. The current 0.71 Current Ratio has changed 933.25% with respect to the historical average. Over the past ten years (40 quarters), KZIA's Current Ratio was at its highest in in the September 2015 quarter at 27.14. The Current Ratio was at its lowest in in the September 2022 quarter at 0.
Average
6.84
Median
2.96
Minimum
0.81
Maximum
25.12
Discovering the peaks and valleys of Kazia Therapeutics Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.99%
Maximum Annual Current Ratio = 25.12
Minimum Annual Increase = -84.80%
Minimum Annual Current Ratio = 0.81
Year | Current Ratio | Change |
---|---|---|
2023 | 1.42 | -12.31% |
2022 | 1.62 | -53.99% |
2021 | 3.53 | 67.89% |
2020 | 2.10 | -46.84% |
2019 | 3.96 | 66.03% |
2018 | 2.38 | -34.16% |
2017 | 3.62 | -84.80% |
2016 | 23.81 | -5.23% |
2015 | 25.12 | 2.99% |
2014 | 0.81 | -55.93% |
The current Current Ratio of Kazia Therapeutics Limited (KZIA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.19
5-year avg
2.53
10-year avg
6.84
Kazia Therapeutics Limited’s Current Ratio is less than CytomX Therapeutics, Inc. (1.00), less than Assembly Biosciences, Inc. (2.74), less than Ocular Therapeutix, Inc. (16.64), less than Spero Therapeutics, Inc. (2.68), less than Achilles Therapeutics plc (8.24), less than SELLAS Life Sciences Group, Inc. (1.02), greater than NLS Pharmaceutics AG (0.23), less than Mereo BioPharma Group plc (6.07), less than Aravive, Inc. (0.98), less than Day One Biopharmaceuticals, Inc. (4.09), greater than ZIVO Bioscience, Inc. (0.17), less than RenovoRx, Inc. (4.39), less than Pasithea Therapeutics Corp. (6.20), less than Quoin Pharmaceuticals, Ltd. (3.35), less than ARCA biopharma, Inc. (26.61), less than Bionomics Limited (3.81), greater than OKYO Pharma Limited (0), less than Candel Therapeutics, Inc. (1.62), less than Anebulo Pharmaceuticals, Inc. (5.32), less than Cingulate Inc. (1.20), less than Nurix Therapeutics, Inc. (5.57), less than Seer, Inc. (17.59), less than Quantum-Si incorporated (20.57), greater than HCW Biologics Inc. (0.10), less than MediciNova, Inc. (18.24),
Company | Current Ratio | Market cap |
---|---|---|
1.00 | $93.74M | |
2.74 | $107.81M | |
16.64 | $1.31B | |
2.68 | $71.07M | |
8.24 | $29.58M | |
1.02 | $76.56M | |
0.23 | $6.09M | |
6.07 | $664.26M | |
0.98 | $2.95M | |
4.09 | $1.25B | |
0.17 | $37.03M | |
4.39 | $24.47M | |
6.20 | $4.37M | |
3.35 | $3.06M | |
26.61 | $34.82M | |
3.81 | $8.81M | |
0 | $36.16M | |
1.62 | $197.00M | |
5.32 | $46.68M | |
1.20 | $12.55M | |
5.57 | $1.50B | |
17.59 | $100.74M | |
20.57 | $129.66M | |
0.10 | $26.62M | |
18.24 | $103.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kazia Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kazia Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Kazia Therapeutics Limited's Current Ratio?
How is the Current Ratio calculated for Kazia Therapeutics Limited (KZIA)?
What is the highest Current Ratio for Kazia Therapeutics Limited (KZIA)?
What is the 3-year average Current Ratio for Kazia Therapeutics Limited (KZIA)?
What is the 5-year average Current Ratio for Kazia Therapeutics Limited (KZIA)?
How does the current Current Ratio for Kazia Therapeutics Limited (KZIA) compare to its historical average?